Increased MI risk linked to dabigatran

A meta-analysis of 11 randomised trials with almost 40,000 participants found patients treated with dabigatran, ximelagatran (which was not brought to market) and the development drug AZD0837 for any indication were 35% more likely to experience an MI than those on warfarin.

A spokesman for Boehringer Ingelheim said doctors could continue to prescribe the drug with confidence as the overall positive benefit-risk ratio for patients with non-valvular atrial fibrillation had been shown in the RE-LY trial.

Am J Cardiol 2013; online 27 September